Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study
- Author
- GRUSON, Berengere1 ; LORTHOLARY, Olivier2 3 ; BARETE, Stephane10 ; SEVESTRE, Henri11 ; DIOUF, Momar12 ; CHABY, Guillaume13 ; MAROLLEAU, Jean-Pierre1 ; DUBREUIL, Patrice14 ; HERMINE, Olivier3 5 ; DAMAJ, Gandhi1 15 3 ; CANIONI, Danielle4 ; CHANDESRIS, Olivia3 5 ; LANTERNIER, Fanny2 3 ; BRUNEAU, Julie4 ; GROSBOIS, Bernard6 ; LIVIDEANU, Cristina7 ; LARROCHE, Claire8 ; DURIEU, Isabelle9
[1] Département d'Hématologie, Centre Hospitalier Universitaire (CHU) d'Amiens, Amiens, France
[2] Département des maladies infectieuses et tropicales, Institut Imagine Hôpital Necker-Enfants Malades, Université Paris Descartes, AP-HP, France
[3] Centre Référence Nationale pour les Mastocytoses, CEREMAST. Hôpital Necker-Enfants Malades, France
[4] Département d'Anatomie Pathologie, AP-HP,Hôpital Necker-Enfants Malades, France
[5] Département d'Hématologie, Institut Imagine, CNRS UMR 8147, AP-HP, Hôpital Necker-Enfants Malades, Université Paris Descartes, Paris, France
[6] Département de Médecine Interne, CHU Pontchaillou, Rennes, France
[7] Département de Dermatologie, CHU de Toulouse, Toulouse, France
[8] Département de Médecine Interne, AP-HP, Hôpital Avicenne, Bobigny, France
[9] Département de Médecine Interne, CHU Lyon-Sud, Lyon, France
[10] Département de Dermatologie et de Maladies Allergiques, APHP,Hôpital Tenon, Université Pierre et Marie Curie, Paris, France
[11] Département d'Anatomie Pathologie, CHU d'Amiens, France
[12] Département de Recherche Clinique, CHU d'Amiens, Amiens, France
[13] Dápartement de Dermatologie, ACHU d'Amiens, Amiens, France
[14] Centre de Cancérologie de Marseille. INSERM U119, Institut Paoli Calmettes, Marseille, France
[15] CNRS UMR 8147, Hôpital Necker-Enfants Malades, Université Paris Descartes, Paris, France - Source
British journal of haematology. 2013, Vol 161, Num 3, pp 434-442, 9 p ; ref : 1 p
- CODEN
- BJHEAL
- ISSN
- 0007-1048
- Scientific domain
- Medical oncology; Hematology
- Publisher
- Blackwell, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- mast cells systemic mastocytosis thalidomide
- Keyword (fr)
- Antiangiogénique Anticancéreux Cancérologie Essai clinique phase II Hématologie Mastocyte Thalidomide Traitement Mastocytose systémique Anti-TNF-alpha Cancer Hémopathie maligne
- Keyword (en)
- Antiangiogenic agent Antineoplastic agent Cancerology Phase II trial Hematology Mast cell Thalidomide Treatment Systemic mastocytosis Anti-Tumor Necrosis Factor-alpha Cancer Malignant hemopathy
- Keyword (es)
- Antiangiogenico Anticanceroso Cancerología Ensayo clínico fase II Hematología Mastocito Talidomida Tratamiento Mastocitosis sistémica Anti-TNF alfa Cáncer Hemopatía maligna
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27282937
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1111/bjh.12265 
https://dx.doi.org/10.1111/bjh.12265
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/bjh.12265\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:93:\"Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"161\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"434\";s:8:\"\u0000*\u0000epage\";s:3:\"442\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"GRUSON\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Berengere\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:19:\"LORTHOLARY, Olivier\";i:1;s:16:\"BARETE, Stephane\";i:2;s:15:\"SEVESTRE, Henri\";i:3;s:12:\"DIOUF, Momar\";i:4;s:16:\"CHABY, Guillaume\";i:5;s:22:\"MAROLLEAU, Jean-Pierre\";i:6;s:17:\"DUBREUIL, Patrice\";i:7;s:16:\"HERMINE, Olivier\";i:8;s:13:\"DAMAJ, Gandhi\";i:9;s:17:\"CANIONI, Danielle\";i:10;s:18:\"CHANDESRIS, Olivia\";i:11;s:17:\"LANTERNIER, Fanny\";i:12;s:14:\"BRUNEAU, Julie\";i:13;s:17:\"GROSBOIS, Bernard\";i:14;s:19:\"LIVIDEANU, Cristina\";i:15;s:16:\"LARROCHE, Claire\";i:16;s:16:\"DURIEU, Isabelle\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:93:\"Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/bjh.12265\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:93:\"Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"161\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"434\";s:8:\"\u0000*\u0000epage\";s:3:\"442\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"GRUSON\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Berengere\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:19:\"LORTHOLARY, Olivier\";i:1;s:16:\"BARETE, Stephane\";i:2;s:15:\"SEVESTRE, Henri\";i:3;s:12:\"DIOUF, Momar\";i:4;s:16:\"CHABY, Guillaume\";i:5;s:22:\"MAROLLEAU, Jean-Pierre\";i:6;s:17:\"DUBREUIL, Patrice\";i:7;s:16:\"HERMINE, Olivier\";i:8;s:13:\"DAMAJ, Gandhi\";i:9;s:17:\"CANIONI, Danielle\";i:10;s:18:\"CHANDESRIS, Olivia\";i:11;s:17:\"LANTERNIER, Fanny\";i:12;s:14:\"BRUNEAU, Julie\";i:13;s:17:\"GROSBOIS, Bernard\";i:14;s:19:\"LIVIDEANU, Cristina\";i:15;s:16:\"LARROCHE, Claire\";i:16;s:16:\"DURIEU, Isabelle\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:93:\"Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/bjh.12265\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/bjh.12265\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:93:\"Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"161\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"434\";s:8:\"\u0000*\u0000epage\";s:3:\"442\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"GRUSON\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Berengere\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:19:\"LORTHOLARY, Olivier\";i:1;s:16:\"BARETE, Stephane\";i:2;s:15:\"SEVESTRE, Henri\";i:3;s:12:\"DIOUF, Momar\";i:4;s:16:\"CHABY, Guillaume\";i:5;s:22:\"MAROLLEAU, Jean-Pierre\";i:6;s:17:\"DUBREUIL, Patrice\";i:7;s:16:\"HERMINE, Olivier\";i:8;s:13:\"DAMAJ, Gandhi\";i:9;s:17:\"CANIONI, Danielle\";i:10;s:18:\"CHANDESRIS, Olivia\";i:11;s:17:\"LANTERNIER, Fanny\";i:12;s:14:\"BRUNEAU, Julie\";i:13;s:17:\"GROSBOIS, Bernard\";i:14;s:19:\"LIVIDEANU, Cristina\";i:15;s:16:\"LARROCHE, Claire\";i:16;s:16:\"DURIEU, Isabelle\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:93:\"Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/bjh.12265\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:93:\"Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"161\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"434\";s:8:\"\u0000*\u0000epage\";s:3:\"442\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"GRUSON\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Berengere\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:19:\"LORTHOLARY, Olivier\";i:1;s:16:\"BARETE, Stephane\";i:2;s:15:\"SEVESTRE, Henri\";i:3;s:12:\"DIOUF, Momar\";i:4;s:16:\"CHABY, Guillaume\";i:5;s:22:\"MAROLLEAU, Jean-Pierre\";i:6;s:17:\"DUBREUIL, Patrice\";i:7;s:16:\"HERMINE, Olivier\";i:8;s:13:\"DAMAJ, Gandhi\";i:9;s:17:\"CANIONI, Danielle\";i:10;s:18:\"CHANDESRIS, Olivia\";i:11;s:17:\"LANTERNIER, Fanny\";i:12;s:14:\"BRUNEAU, Julie\";i:13;s:17:\"GROSBOIS, Bernard\";i:14;s:19:\"LIVIDEANU, Cristina\";i:15;s:16:\"LARROCHE, Claire\";i:16;s:16:\"DURIEU, Isabelle\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:93:\"Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/bjh.12265\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:93:\"Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"161\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"434\";s:8:\"\u0000*\u0000epage\";s:3:\"442\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"GRUSON\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Berengere\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:19:\"LORTHOLARY, Olivier\";i:1;s:16:\"BARETE, Stephane\";i:2;s:15:\"SEVESTRE, Henri\";i:3;s:12:\"DIOUF, Momar\";i:4;s:16:\"CHABY, Guillaume\";i:5;s:22:\"MAROLLEAU, Jean-Pierre\";i:6;s:17:\"DUBREUIL, Patrice\";i:7;s:16:\"HERMINE, Olivier\";i:8;s:13:\"DAMAJ, Gandhi\";i:9;s:17:\"CANIONI, Danielle\";i:10;s:18:\"CHANDESRIS, Olivia\";i:11;s:17:\"LANTERNIER, Fanny\";i:12;s:14:\"BRUNEAU, Julie\";i:13;s:17:\"GROSBOIS, Bernard\";i:14;s:19:\"LIVIDEANU, Cristina\";i:15;s:16:\"LARROCHE, Claire\";i:16;s:16:\"DURIEU, Isabelle\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:93:\"Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
